There is no consensus on optimal screening for anal cancer (AC) in HIV+ women. 715 unique asymptomatic women in a high-prevalence HIV+ community were screened for AC with anal cytology and triage to high-resolution anoscopy (HRA) after routine screening was implemented in a large urban hospital system. Of these, 75(10.5%) had an abnormal anal cytology and 29(38.7%) with an abnormality had high grade AIN.
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Introduction:
The incidence of anal carcinoma (AC) has been increasing despite the implementation of ART, which has not been shown to consistently alter the course of HPV-associated anogenital disease 1 . Anal cancer in specific populations, such as people living with HIV/AIDS, has been increasing at alarming rates.
2 This is likely due to the fact that HIV promotes HPV persistence and consequently, HIV-infected individuals are also at increased risk for the development of HPV-associated neoplasms 1, 3, 4, 5 . Across all strata of HIV control, HPV rates and abnormal anal cytology are exceedingly high 6 . In fact, studies in HIV-infected women show that HPV prevalence in the anal canal is higher than in the cervical-vaginal tract 1, 6, 3 . The incidence of AC in HIV+ men who have sex with men (MSM) is 10-50 times that of the general population, and comparable to cervical cancer incidence rates prior to implementation of cervical cancer screening (40-50/100,000) 7 . Similar to the cervix, the anus is susceptible to neoplastic transformation as a result of persistent HPV at the anal dentate line between squamous and columnar cells. In women with HIV/AIDS, the incidence of AC is 7-28 times greater than the general population 6, 8 . This relatively recent phenomenon was probably masked in the pre-ART era, when HIV-infected patients typically succumbed to an AIDS-defining illness soon after initial HIV infection. Now that they are living longer with ART, these patients are at risk for non-AIDS-defining malignancies such as AC.
Treatment for AC is usually associated with significant morbidity and mortality in advanced disease, which highlights the importance of improving screening strategies for its precursor lesions 9 . Bronx County has one of the highest HIV prevalence rates in the US with 1.8% of the population known to be HIV infected, representing 3% of the total US HIV burden.
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Montefiore Medical Center is the largest provider of medical services for people with HIV in the Bronx and has adopted routine screening for AC with annual anal cytology in all HIV-infected patients. In the ART era, little data exists regarding the prevalence of anal HPV and AIN among HIV-infected women 3, 6, 16, 17 . Most prior studies are in MSM with HIV. Therefore, extrapolation of anal cytology prevalence to HIV-infected women is likely inaccurate given the lower disease prevalence rates. The purpose of this study is to determine the prevalence of high grade AIN in asymptomatic, HIV-infected women during the implementation period of routine AC screening in an urban hospital system. and then retrospectively reviewed. Providers screened all HIV-infected women with anal cytology at the time of a routine visit using a Dacron swab that was inserted into the anal canal and rotated as previously described 18, 19 , then sent in liquid-based media (SurePath™, BD, NJ) to the hospital-based cytopathology laboratories for analysis. As part of the adoption and tracking during implementation, when patients reported anogenital warts or providers identified obvious anogenital warts, this was noted in patient charts. These patients were not 'asymptomatic' screens and as such were not included in the analysis. Anal cytology results were categorized according to the Bethesda system for cervical cytology: normal; atypical squamous cells; low-grade squamous intraepithelial lesions (LSIL); and high-grade squamous intraepithelial lesions (HSIL). Women with unsatisfactory anal cytology results were excluded from classification. Anal histological results were categorized as normal, condyloma, AIN1, AIN2, and AIN3. All women with abnormal anal cytology were referred for HRA and subsequent biopsy of abnormal lesions by one of two trained surgical providers (ME and DS). In cases where a patient had more than one anal cytology during this time period, subject information was counted only once. In these cases, the highest grade AIN from HRA-directed biopsy from any of the visits was used for this analysis.
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Baseline clinical and HIV-related data were obtained from chart review after IRB approval. HIV control was defined for each patient as poor, moderate, or well-controlled based on their CD4 T-cell count and viral load (VL). In brief, those with CD4>500 cells/mm 3 and undetectable VL were characterized as well-controlled. Those with CD4
<250 and detectable VL were defined as poorly-controlled. All other patients are defined as moderately-controlled. The association of high grade anal dysplasia with HIV status was performed using Fisher's exact test. A Kappa coefficient was calculated to determine the agreement between anal cytology and HRA-directed biopsy.
Results:
Screening with anal cytology was performed on 715 unique HIV-infected women The clinical and demographic characteristics of patients undergoing HRA (Table   1) is typical for the HIV population in Bronx, NY, in that they were ethnically and racially diverse. Sixty-one percent smoked, and 79% had a diagnosis of AIDS. The median Results of the HRA directed biopsy(ies) stratified by anal cytology are provided in Table 2 ). For example, 11/18 (61%) with poorly controlled HIV infection had high grade AIN, but only 1/20 (5%) with well-controlled HIV had high grade AIN (p=0.03).
Discussion:
In this contemporary cohort of asymptomatic HIV+ women, the rate of abnormal anal cytology is very high (10.5%). However, this is lower than what has previously been reported in the literature, with rates between 17-33% 3, 6, 16, 17 . This might be attributable to the variation in cytopathological interpretation 20 . In women with abnormal cytology, we found an impressively high rate of high-grade AIN determined by
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HRA-directed biopsy (38.3%). This is significantly higher than results previously reported, ranging from 6.7% for all AIN in a study by Abramowitz et al. to 21.4%. 21, 6, 17 Additionally, although most of this cohort was maintained on ART, the rate was not as high as the general HIV clinic population and compared to previous reports 22, 17, 16 ,our study includes a higher percentage of poorly-controlled HIV+ subjects, with 34.7%
having a CD4 T-cell count <200 cells/mm Second, anal cytology performance has been shown to vary depending on the level of HIV virologic suppression and extent of the disease 18, 19 . Given the relatively poor performance of identification of high grade AIN with anal cytology, other strategies that may improve screening performance should be explored, including innovative sampling devices or use of molecular testing strategies in combination with cytology. Considering the lower disease prevalence and anal HPV prevalence in HIV-infected women when compared to HIV-infected MSM 6 , inclusion of HPV testing in a triage algorithm for welldefined clinical groups of HIV-infected women might be a more optimal strategy for triage to HRA. There are a number of trials in the planning stages in the US to assess such alternative strategies in women.
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Our study has multiple limitations. HRA-directed biopsies were only performed on those patients with abnormal anal cytology. There are likely false-negative anal cytology tests in this population, which likely underestimated the disease prevalence and affects the sensitivity of anal cytology. Also, because this study was done soon after the adoption of AC screening, and before the practice became more universally adopted in our population, the screened population may differ from the general population of HIV-infected patients. Providers may have been more likely to screen patients they consider at higher risk for HPV infection. This point is reinforced with the lower rate of ART use in this cohort than in the general HIV population. Nearly 10% of patients refused to have biopsies. Since the analysis was done only in those who had HRA-directed biopsies, this may have impacted sensitivity calculations and univariate associations with clinical and demographic characteristics. In those who underwent biopsy, some of these subjects had delays (up to 9 months) from time of initial anal cytology to HRA. During this time, the disease might have worsened, with a minority potentially regressing, falsely increasing our prevalence of high grade AIN. As part of tracking, providers were asked to document patient complaints and objective findings of obvious anogenital warts. Despite this, the prevalence of condyloma in this group is probably underestimated, given the high prevalence of asymptomatic condylomata detected with HRA. Also, there was limited information regarding the prior AC screening histories of this patient population. However, given that this population is communitybased and their care has been provided by the same team of providers since their HIV diagnosis, the vast majority of these patients were AC screening naïve. HPV testing was not performed in these patients because it is not currently recommended.
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Therefore, the utility of HPV testing could not be assessed with regards to disease risk stratification. Larger comprehensive prospective screening studies for AC prevention in the setting of HIV for both women and men are clearly needed.
In conclusion, until we have validated, optimized screening strategies for AC in the setting of HIV, we recommend that all HIV+ women who have any abnormal anal cytology be referred for HRA, particularly those with poorly controlled HIV who are significantly at even higher risk for harboring a high grade AIN than women who are well-controlled. Given the lower high grade AIN disease prevalence in women with wellcontrolled HIV, other strategies to improve disease ascertainment, such as inclusion of HPV testing might be found to be useful for AC screening optimization in prospective studies. This risk stratification might prove to be different for women than it is for men, and particularly MSM, where prevalence rates appear to be considerably higher. Given 
